-
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer -
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate -
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002 -
Volastra Therapeutics Named One Of Fierce Biotech’s “Fierce 15” Companies Of 2022
Volastra Therapeutics Named One Of Fierce Biotech’s “Fierce 15” Companies Of 2022 -
Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration
Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration -
Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic
Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic -
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO -
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology
Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology -
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines -
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months -
Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
-
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology